Tests immune cells that target lung cancer in people with lung cancer
Tests lab-treated immune cells aimed at lung cancer markers in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Antigen-specific T Cells Against Lung Cancer
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with stage III, IV or relapsed lung cancer who can receive cancer antigen-specific T cells.
- Age
- 18 to 80 years.
- Sex
- All sexes can join.
- Disease stage
- Stage III, IV or relapsed lung cancer, confirmed by histology and biopsy.
- Earlier treatment
- At least 4 weeks since the last chemotherapy or radiotherapy, and at least 2 weeks since the last systemic steroid or other immunosuppressive treatment. Side effects of chemotherapy must have subsided.
- Biomarker or test result
- Cancer-specific antigens must be identified and show high levels (>2+) in tumour tissue by immunostaining or flow cytometry.
Main reasons for not taking part
- Airway blocked by the tumour
- History of epilepsy or other central nervous system disease
- Needs systemic corticosteroid or other immunosuppressive treatment
- Pregnant or breastfeeding
- Active HIV, hepatitis B or hepatitis C infection, or an uncontrolled or serious active infection
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT03356808, who can take part
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaContact: Lung-Ji Chang, PhDNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT03356808
- Record updated
- 2 November 2026
- Original description
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.Read full original descriptionShow less
Multicenter Trial of Cancer Antigen-specific T Cells in the Treatment of Lung Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer. The cancer targeting antigens are identified through immunostaining of patient's cancer specimens. Another goal of the study is to learn more about the persistence and function of the ex vivo manipulated antigen-specific T cells in the body.
Inclusion: Patients with stage III, IV or relapsed lung cancer confirmed by histology and biopsy; Age: ≥ 18 years and ≤ 80 years; 4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy; Side Effects of Chemotherapy have subsided; Cancer specific antigens are identified and shown to express at high levels (>2+) in malignant tissues by immuno-histochemical staining or flow cytometry; Karnofsky/Lansky ≥ 50%; Expected survival ≥ 6 weeks; Initial hematopoietic conditions with; neutrophils (ANC) ≥ 1×10\^6/L; platelet (PLT) ≥ 1×10\^8/L; Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with; serum creatinine ≤ 2×ULN; serum bilirubin ≤ 3×ULN; AST/ALT ≤ 5×ULN; Oxygen saturation ≥ 90%. 11. Written, informed consent obtained prior to any study-specific procedures.
Exclusion: Patients who require systemic corticosteroid or other immunosuppressive therapy; Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in any immune cell therapy study; Inadequate liver and renal function with; History of epilepsy or other central nervous system diseases; history of serious cyclophosphamide toxicity; History of prolonged or serious heart disease during QT; serum creatinine > 2.5 mg/dl; serum (total) bilirubin > 2.0 mg/dl; AST \& ALT > 3 x ULN; Pregnant or lactating females. 9. Serious active infection during screening. 10. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection; Patients, in the opinion of investigators, may not be eligible or not able to comply with the study; Airway obstruction caused by tumor.